In lapatinib-treated patients , the overall risk for National Cancer Institute-Common Terminology Criteria for Adverse Events grade @ ALT elevation ( > @ upper limit of normal ) was @ % ; HLA allele carriers had an increased risk of @ % ; in noncarriers , risk was reduced to @ % , comparable to ALT elevation for all patients receiving placebo .